Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19

Fulgent Genetics, Inc.

Fulgent Genetics, Inc.

FLGT

0.00

Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ: FLGT) with a Neutral and raises the price target from $15 to $19.